Overview
Thymosin Alpha-1 is classified as a immune peptide peptide. Immune support, antiviral, recovery.
Enhances T-cell function, boosts dendritic cell activity, and modulates cytokine production. Shifts immune response toward effective pathogen clearance.
Also known as: Tα1, Zadaxin
Category
Immune Peptide
Half-Life
2h
Route
SubQ
FDA Status
Not Approved
How Does Thymosin Alpha-1 Work?
Enhances T-cell function, boosts dendritic cell activity, and modulates cytokine production. Shifts immune response toward effective pathogen clearance.
At the molecular level, Thymosin Alpha-1 operates through pathways characteristic of the Immune Peptide class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]Thymosin Alpha-1 in immune-compromised patients
Garaci et al.: Review of Tα1 use in immune-compromised patients showing enhanced T-cell function, improved dendritic cell activity, and cytokine modulation.
Evidence: moderate strong[2]Thymosin Alpha-1 safety/efficacy: review of 30+ clinical trials
King & Tuthill: Comprehensive review of 30+ clinical trials involving 11,000+ subjects confirming Tα1's consistent safety and efficacy across hepatitis B/C, cancer, and infections.
Evidence: strong[3]Thymosin Alpha-1 as adjunct in hepatitis B treatment
Mutchnick et al. (Hepatology): Randomized trial showing Tα1 combined with interferon significantly improves virologic response in chronic hepatitis B vs. interferon alone.
Evidence: strong[4]Thymosin Alpha-1 in sepsis and critical care
Evidence review of Tα1 in septic shock, ARDS, and peritonitis showing improved survival and immune recovery in critically ill patients.
Evidence: moderate strong[5]Thymosin Alpha-1 as cancer immunotherapy adjuvant
Garaci et al. (Ann. N.Y. Acad. Sci.): Review of Tα1 as cancer immunotherapy adjunct, showing enhanced chemotherapy tolerance and improved immune recovery in multiple tumor types.
Evidence: moderateSafety Profile
Approved in 35+ countries for hep B/C. One of the most extensively studied peptides. Not FDA-approved in US.
| Side Effect | Incidence | Severity |
|---|---|---|
| Injection site reaction | ~5% of users | mild |
| Mild flu-like symptoms (immune activation) | ~5% of users | mild |
Sourcing Thymosin Alpha-1 for Research
If you're looking to source Thymosin Alpha-1 for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
Disclosure: PeptiDex may earn a commission from affiliate links. This does not affect our recommendations.
Full Research Profile
Thymosin Alpha-1 — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.